IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation	Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm	Recruiting	Phase 2	2026-03-11		NCT07198841

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Guangdong Association of Clinical Trials	20
Innovent Biologics (Suzhou) Co. Ltd.	82
Mabpharm Limitied	1

7 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Affiliated Tumor Hospital of Guangxi Medical University	Nanning	China	1
Chinese PLA General Hospital	Beijing	China	39
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University,	Guangzhou	China	2
The First Affiliated Hospital of Nanchang University	Nanchang	China	55
The First People's Hospital of Foshan	Foshan	China	11
The Fourth Hospital of Hebei Medical University	Shijiazhuang	China	16
The Second Affiliated Hospital of Nanchang University	Nanchang	China	29